BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

51 related articles for article (PubMed ID: 9756005)

  • 1. The importance of initial daily administration of interferon alpha for the eradication of hepatitis C virus in patients with chronic hepatitis C: a multicenter randomized trial.
    Nakamura H; Ito H; Kimura Y; Takeda A; Ogawa H; Kanazawa S; Kuroda T; Inada M; Harada H; Kishimoto T; Zenda S; Terabayashi M; Saeki K; Wada M; Igarashi A; Uemiya M; Kobayashi Y; Hayashi E
    Hepatogastroenterology; 1998; 45(22):1045-55. PubMed ID: 9756005
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Initial daily interferon administration can gain more eradication of HCV-RNA in patients with chronic hepatitis C, especially with serum intermediate viral load.
    Nakamura H; Ito H; Ogawa H; Takeda A; Kanazawa S; Kuroda T; Yamamoto M; Enomoto H; Kimura Y; Zenda S; Terabayashi M; Saeki K; Noguchi S; Hara H; Uemiya M; Igarashi A; Hayashi E
    Hepatogastroenterology; 1999; 46(26):1131-9. PubMed ID: 10370680
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interferon treatment for patients with chronic hepatitis C infected with high viral load of genotype 2 virus.
    Nakamura H; Ogawa H; Kuroda T; Yamamoto M; Enomoto H; Kishima Y; Yoshida K; Ito H; Matsuda M; Noguchi S
    Hepatogastroenterology; 2002; 49(47):1373-6. PubMed ID: 12239945
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A pilot study of combination therapy with initial high-dose interferon and amantadine hydrochloride for patients with chronic hepatitis C with the genotype 1b virus.
    Uyama H; Enomoto H; Kishima Y; Yamamoto M; Yoshida K; Okuda Y; Hirotani T; Kuroda T; Ito H; Matsuda M; Terabayashi M; Noguchi S; Kawase I; Nakamura H
    Hepatogastroenterology; 2003; 50(54):2112-6. PubMed ID: 14696476
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of prolonged interferon therapy for patients with chronic hepatitis C with HCV-genotype 1b and high virus load.
    Arase Y; Ikeda K; Tsubota A; Suzuki Y; Saitoh S; Kobayashi M; Kobayashi M; Suzuki F; Akuta N; Someya T; Kumada H
    J Gastroenterol; 2003; 38(2):158-63. PubMed ID: 12640530
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The combination therapy of interferon and amantadine hydrochloride for patients with chronic hepatitis C.
    Nakamura H; Uyama H; Enomoto H; Kishima Y; Yamamoto M; Yoshida K; Okuda Y; Hirotani T; Kuroda T; Ito H; Matsuda M; Terabayashi M; Noguchi S
    Hepatogastroenterology; 2003; 50(49):222-6. PubMed ID: 12630027
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination of ribavirin and interferon-alfa surpasses high doses of interferon-alfa alone in patients with genotype-1b-related chronic hepatitis C.
    Pol S; Nalpas B; Bourlière M; Couzigou P; Tran A; Abergel A; Zarski JP; Berthelot P; Bréchot C
    Hepatology; 2000 Jun; 31(6):1338-44. PubMed ID: 10827161
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Studies of the effectiveness of interferon alpha treatment for chronic hepatitis C in children.
    Czerwionka-Szaflarska M; Chrobot A; Szaflarska-Szczepanik A
    Med Sci Monit; 2000; 6(5):964-70. PubMed ID: 11208439
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is interferon-alpha therapy safe and effective for patients with chronic hepatitis C and inflammatory bowel disease? A case-control study.
    Bargiggia S; Thorburn D; Anderloni A; Ardizzone S; Giorgi A; Bianchi Porro G; Parente F
    Aliment Pharmacol Ther; 2005 Aug; 22(3):209-15. PubMed ID: 16091058
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Twice-a-day versus once-a-day interferon-beta therapy in chronic hepatitis C.
    Kaito M; Yasui-Kawamura N; Iwasa M; Kobayashi Y; Nakagawa N; Fujita N; Ikoma J; Gabazza EC; Watanabe S; Adachi Y
    Hepatogastroenterology; 2003; 50(51):775-8. PubMed ID: 12828083
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized controlled trial of lymphoblastoid interferon alpha for chronic hepatitis C (comparison of 9-MU and 6-MU doses). IFN Treatment Group of Affiliated Hospitals of the Third Department of Internal Medicine at Nagoya University School of Medicine.
    Yoshioka K; Yano M; Kusakabe A; Hirofuji H; Fuji A; Kuriki J; Arao M; Murase K; Kidokoro R; Kakumu S
    Am J Gastroenterol; 1999 Jan; 94(1):164-8. PubMed ID: 9934749
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of natural BALL-1 interferon-alpha treatment for patients with chronic hepatitis C and a possible enhancing effect of a twice-daily starting regimen with interferon-beta.
    Ebinuma H; Saito H; Tada S; Nakamoto N; Kurita S; Kitamaura K; Horikawa H; Kumagai N; Tsuchimoto K; Ishii H; Hibi T;
    Hepatogastroenterology; 2006; 53(67):94-9. PubMed ID: 16506384
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interferon treatment of chronic hepatitis C in patients cured of pediatric malignancies.
    Cesaro S; Bortolotti F; Petris MG; Brugiolo A; Cusinato R; Guido M; Rossetti F; Masiero L; Zanesco L
    Haematologica; 2000 Jan; 85(1):63-6. PubMed ID: 10629594
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of interferon retreatment after relapse for chronic hepatitis C patients with biochemical response after first interferon therapy.
    Arase Y; Ikeda K; Tsubota A; Suzuki Y; Saitoh S; Kobayashi M; Suzuki F; Akuta N; Someya T; Hosaka T; Kobayashi M; Kumada H
    J Gastroenterol; 2004; 39(5):455-60. PubMed ID: 15175944
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Daily interferon therapy for chronic hepatitis C: a report of a community practice experience.
    Srinivas D; Mani H; Crumpler C; Van Thiel DH
    Hepatogastroenterology; 2002; 49(46):1053-7. PubMed ID: 12143200
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Study of the relapse of patients with chronic hepatitis B undergoing first and repeated recombinant interferon-alpha therapy during long-term follow up].
    Liu DL; Luo KX; Feng XR; Fu QX; Hou JL
    Zhonghua Yi Xue Za Zhi; 2007 Jul; 87(26):1840-3. PubMed ID: 17922996
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chronic hepatitis C virus infection in renal transplant: treatment and outcome.
    Sharma RK; Bansal SB; Gupta A; Gulati S; Kumar A; Prasad N
    Clin Transplant; 2006; 20(6):677-83. PubMed ID: 17100715
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sequential changes of hepatitis C virus antibody profiles during treatment of chronic hepatitis C of genotype 1b: pretreatment antibody response to E2/NS1 correlated sustained response.
    Chu CM; Sheen IS; Liaw YF
    Infection; 2004 Jun; 32(3):153-6. PubMed ID: 15188075
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A potent antiviral effect on hepatitis C viral dynamics in serum and peripheral blood mononuclear cells during combination therapy with high-dose daily interferon alfa plus ribavirin and intravenous twice-daily treatment with interferon beta.
    Asahina Y; Izumi N; Uchihara M; Noguchi O; Tsuchiya K; Hamano K; Kanazawa N; Itakura J; Miyake S; Sakai T
    Hepatology; 2001 Aug; 34(2):377-84. PubMed ID: 11481623
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical impact of genotype 1 TT virus infection in patients with chronic hepatitis C and response of TT virus to alpha-interferon.
    Nishizawa Y; Tanaka E; Orii K; Rokuhara A; Ichijo T; Yoshizawa K; Kiyosawa K
    J Gastroenterol Hepatol; 2000 Nov; 15(11):1292-7. PubMed ID: 11129224
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.